The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth
Open accessAbstract
// Ningning Liu 1,2,* , Xiaofen Li 1,* , Hongbiao Huang 1,* , Chong Zhao 1,* , Siyan Liao 1,* , Changshan Yang 1,* , Shouting Liu 1,* , Wenbin Song 1 , Xiaoyu Lu 1 , Xiaoying Lan 1 , Xin Chen 1 , Songgang Yi 1 , Li Xu 1,3 , Lili Jiang 1 , Canguo Zhao 1 , Xiaoxian Dong 1 , Ping Zhou 1 , Shujue Li 1,4 , Shunqing Wang 1 , Xianping Shi 1 , Ping Q. Dou 1,5 , Xuejun Wang 1,6 , and Jinbao Liu 1 1 State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Department of Pathophysiology, Guangzhou Medical University, Guangdong, China 2 Guangzhou Research Institute of Cardiovascular Disease, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China 3 Department of Hematology, The People’s Hospital of Guangxi Autonomous Region, Nanning, Guangxi, People’s Republic of China 4 Guangzhou Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China 5 The Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, Michigan, USA 6 Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, South Dakota, USA * These Authors contributed equally to this work Correspondence: Jinbao Liu, email: // Keywords : cancer, deubiquitinase, proteasome, auranofin Received : April 7, 2014 Accepted : June 17, 2014 Published : June 18, 2014 Abstract Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative evaluation of 11 scoring functions for molecular docking.
Wang, R., Lu, Y., & Wang, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0203783 · Cited by 849
Self-citation
Cited by
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Chemical biology of anticancer gold(iii) and gold(i) complexes
Zou, T., Lum, C. T., Lok, C.-N., Zhang, J.-J., & Che, C.-M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00132c · Cited by 628
Oxidative cell death in cancer: mechanisms and therapeutic opportunities
An, X., Yu, W., Liu, J., Tang, D., Yang, L., & Chen, X. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06939-5 · Cited by 523
Self-citationAuranofin: Repurposing an Old Drug for a Golden New Age
Roder, C., & Thomson, M. J. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0083-y · Cited by 497
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
Metadata
- Authors
- Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., Liu, S., Song, W., Lu, X., Lan, X., Chen, X., Yi, S., Xu, L., Jiang, L., Zhao, C., Dong, X., Zhou, P., Li, S., Wang, S., Shi, X., Dou, P. Q., Wang, X., & Liu, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-06-18
- Volume
- 5
- Issue
- 14
- Pages
- 5453-5471
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2112932498
- Cited by
- 173
- References
- 1
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.